Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Following discussions over the last weeks, the French State and Eramet have reached an agreement regarding the treatment of SLN's existing debt. This agreement will neutralize SLN's debt impact on the ...

Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.7% in the last trading session to close at $22.36. The move was backed by solid volume with far more shares changing hands than in a normal ...

With a view to the signing of the Pacte Nickel (Nickel Pact), Eramet and the French State have reached an agreement to extend the financial guarantees granted to SLN, enabling SLN to continue to run ...

Silence Therapeutics plc Buy: siRNA progress in PV & ASCVD, divesiran SANRECO data and Aug 2026 catalyst; watch cash ...

Silence Therapeutics PLC Sponsored ADR (SLN) shares rallied 19% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being ...

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...

View Silence Therapeutics PLC Sponsored ADR SLN stock quote prices, financial information, real-time forecasts, and company news from CNN.